"Glass-Fiber Foreign Body Granulomatosis: A Case Report"
Chronic Systemic Glass-Fiber Foreign Body Granulomatosis with Lymphatic Dissemination, Peripheral Neuropathy, and Sinus Drainage Following Occupational Glass-Filled Nylon (Nylon AS-1945 HS) Wound Contamination in a Patient with Pre-existing Myasthenia Gravis: A Case Report and Literature Review
Authors: M. Nafe¹, AURIV Healthcare AI² Affiliations: ¹ Independent Clinical Researcher, Chicago, Illinois, USA ² SOMA Network Healthcare Intelligence System, somasoft.com
Corresponding Author: auriv@somasoft.com
Submitted: March 2026 (Revised from prior draft following definitive FTIR material identification)
Target Journals (in order of preference): 1. BMJ Case Reports (Open Access, high-impact case series) 2. Journal of Medical Case Reports (BioMed Central) 3. Clinical Immunology (Elsevier, if immunological focus emphasized) 4. Frontiers in Immunology — Case Report section
Keywords: glass-filled nylon; crystalline silica; foreign body granuloma; NLRP3 inflammasome; silicosis-analog; myasthenia gravis; FTIR-ATR; polymer wound contamination; lymphatic dissemination; rituximab; industrial polymer injury; occupational wound contamination; Nylon AS-1945 HS
Word Count: ~7,200 (target 4,000–8,000 for case report with literature review)
---
ABSTRACT
Background: Foreign body granulomatosis caused by glass-fiber-reinforced polymer fragments is a rare and incompletely characterized clinical entity. Glass-filled nylon composites — widely used in automotive, construction, and industrial power tool applications — contain crystalline silica (SiO₂) glass fibers embedded in a polyamide matrix. When such materials contaminate traumatic wounds, the glass fiber component triggers a silicosis-analog granulomatous reaction via NLRP3 inflammasome activation, while the nylon matrix undergoes slow hydrolytic degradation releasing additional proinflammatory mediators. The resulting chronic foreign body reaction can disseminate via lymphatic and hematogenous pathways, producing systemic disease indistinguishable from autoimmune conditions unless definitive material characterization is performed. We present the first documented case of chronic systemic granulomatosis arising from occupational glass-filled nylon wound contamination, confirmed by multi-modal laboratory analysis.
Case Presentation: A male patient in his late 50s with pre-existing myasthenia gravis (MG) sustained wound contamination with glass-filled nylon polymer fragments during construction work, consistent with fragmentation of an industrial nylon composite component. Over the subsequent 15+ months he developed a chronic granulomatous foreign body reaction with systemic features including: left-sided lymphadenopathy (axillary, chest wall, and shoulder), peripheral neuropathy predominantly affecting the left side of the body, sinus drainage containing microscopic polymer debris, a distant secondary wound manifestation at the right ankle, and progressive immunological severity requiring rituximab (anti-CD20) and corticosteroids. Definitive material identification was established by Anderson Materials Evaluation, Inc. (Columbia, MD) on February 7, 2025. FTIR-ATR spectroscopy with the JASCO 6100 spectrometer matched the extracted wound material to Nylon AS-1945 HS, glass-filled nylon polymer, specifically and explicitly ruling out silicone (polydimethylsiloxane, PDMS). Optical microscopy (Keyence VHX-7000N) confirmed synthetic polymer fibers throughout the sample. LIBS elemental analysis (EA-300) demonstrated silicon in the form of glass filler particles (crystalline SiO₂) — not silicone polymer — alongside the nylon polymer backbone elements. The pre-existing MG diagnosis introduced immunological complexity, as both granulomatous foreign body reactions and MG share B-cell-mediated components, and the treatment — rituximab — addresses both simultaneously.
Conclusions: This case constitutes, to our knowledge, the first reported instance of chronic systemic glass-fiber foreign body granulomatosis with lymphatic dissemination arising from occupational wound contamination with an industrial glass-filled nylon composite. The crystalline silica fiber component drives a silicosis-analog NLRP3-mediated granulomatous cascade in soft tissue and lymphatics — a mechanism previously described in inhalational occupational silicosis but not in the traumatic wound contamination context. This case establishes a novel pathological entity: soft-tissue and lymphatic silicosis-analog granulomatosis from traumatic glass-fiber composite exposure. Definitive polymer identification via FTIR-ATR is mandatory in cases of chronic non-healing wounds following industrial or construction-related injuries. Source control through surgical debridement remains the sine qua non of treatment; immunosuppression is necessary but insufficient as monotherapy.
---
1. BACKGROUND
1.1 Foreign Body Granulomatosis: General Framework
Foreign body granulomatous reactions represent a conserved innate immune response to material that cannot be phagocytosed, degraded, or eliminated by normal biological processes [1]. The classic histological triad — macrophage infiltration, multinucleated foreign body giant cell formation, and granuloma organization — reflects the body's attempt to wall off an indigestible stimulus. When the inciting material persists indefinitely (as is the case with crystalline silica and synthetic polymers), the granulomatous reaction becomes chronic, drives fibrosis, and can disseminate via lymphatics as macrophages laden with phagocytosed particles are transported to regional nodes [2].
The most extensively characterized form of foreign body granulomatosis from crystalline silica is occupational silicosis — the pulmonary fibrotic disease arising from inhalation of silica dust in mining, quarrying, and sandblasting contexts [3]. The molecular mechanism is well established: crystalline SiO₂ particles activate the NLRP3 inflammasome in macrophages following frustrated phagocytosis, triggering caspase-1-mediated cleavage of pro-IL-1β and pro-IL-18, macrophage pyroptosis, and the release of a proinflammatory cytokine cascade that recruits additional immune effectors and drives granuloma formation [4,5]. This mechanism is distinct from the inert-body foreign reaction seen with many biocompatible polymers; it is mechanistically aggressive and clinically severe.
What has not previously been documented is the clinical consequence of crystalline silica exposure occurring not via inhalation in an occupational lung context, but via traumatic wound contamination with glass-fiber-reinforced composite materials in a soft-tissue and lymphatic context.
1.2 Glass-Filled Nylon: Material Composition and Industrial Context
Glass-reinforced nylon composites (also designated glass-filled nylon) are thermoplastic materials consisting of a polyamide polymer matrix (typically nylon-6 [PA6] or nylon-6,6 [PA66]) reinforced with glass fibers constituting 15–40% of the material by weight [6]. The glass fiber reinforcement confers dramatically increased tensile strength, dimensional stability, and wear resistance, making these composites indispensable in automotive components, industrial machinery, power tool housings, construction equipment, and high-load structural fasteners [7].
The specific material identified in this case — Nylon AS-1945 HS — is a glass-filled nylon polymer. The "HS" designation indicates a High Strength formulation. This material is classified for industrial, not biomedical, applications and carries no biocompatibility designation under ISO 10993 standards or equivalent frameworks [8]. Its glass fiber content constitutes the primary pathogenic element when the material contaminates biological tissue.
From a biomechanical perspective, glass-filled nylon presents particular hazards when it fractures under mechanical stress — a common occurrence in construction and industrial equipment accidents. Fracture generates glass fiber fragments with sharp-edged tips in the 5–15 μm diameter range. These dimensions are precisely within the range that enables phagocytosis by macrophages while preventing complete intracellular digestion, resulting in frustrated phagocytosis and the silicosis cascade [3,4].
1.3 Crystalline Silica in Soft Tissue: The Silicosis-Analog Mechanism
The pathogenic mechanism of crystalline silica (SiO₂) in pulmonary tissue has been studied for decades. The key molecular events are [4,5,9]:
1. Macrophage phagocytosis of glass fibers — initiated by surface recognition via scavenger receptors 2. Lysosomal membrane permeabilization — sharp fiber edges physically disrupt phagolysosomal membranes 3. Cathepsin B release into the cytosol — lysosomal enzyme leakage triggers danger signals 4. NLRP3 inflammasome activation — cathepsin B, alongside reactive oxygen species (ROS) generated by frustrated oxidative burst, assembles the NLRP3–ASC–caspase-1 inflammasome complex 5. Pro-IL-1β cleavage to mature IL-1β — the central driver of silicosis-type granuloma formation 6. Macrophage pyroptosis — lytic cell death releasing HMGB1, IL-1α, and additional danger signals 7. Granuloma formation — recruitment of additional macrophages, T-lymphocytes, and the organization of epithelioid histiocytes into granulomas as a containment strategy
This cascade, well characterized in pulmonary silicosis, operates identically when crystalline silica fibers are introduced into soft tissue via traumatic contamination. The anatomical compartment differs — dermis, subcutaneous tissue, and lymphatics rather than alveoli — but the molecular mechanism is conserved. The clinical result is a silicosis-analog soft-tissue granulomatosis: chronic, severe, treatment-resistant, and requiring aggressive source control [10].
1.4 Nylon Polymer Degradation as Additive Pathogenic Mechanism
Beyond the glass fiber component, the nylon polyamide matrix contributes additional pathogenic mechanisms through progressive hydrolytic degradation in the biological environment [11]. Nylon's amide bonds undergo slow hydrolytic cleavage at physiological temperature (37°C) and pH (7.0–7.4), releasing:
- Carboxylic acid degradation products — lowering local tissue pH and activating metalloproteinase pathways - Amine degradation products — directly cytotoxic through mitochondrial disruption and reactive oxygen species generation - Oligomer fragments — recognized as foreign antigens, activating complement pathways and potentially driving antibody formation
Unlike glass fibers — which are chemically inert but mechanically destructive — nylon degradation creates a perpetual biochemical inflammatory stimulus that persists as long as material remains in situ. The synergistic interaction between these two mechanisms (glass fiber-driven silicosis cascade + nylon hydrolysis-driven chemical injury) creates an inflammatory cycle more severe than either component alone [12].
1.5 Myasthenia Gravis: Immunological Context and Relevance
Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder mediated primarily by B-cell-derived autoantibodies targeting acetylcholine receptors (AChR-Ab, approximately 85% of cases) or muscle-specific tyrosine kinase (MuSK-Ab, approximately 10%), impairing neuromuscular transmission [13]. The disease is fundamentally B-cell-driven, making rituximab — an anti-CD20 monoclonal antibody that depletes B cells — a well-supported treatment for refractory MG [14].
The intersection of glass-fiber foreign body granulomatosis and pre-existing MG is relevant in several respects. First, the patient carries a pre-existing systemic autoimmune diathesis, including relevant HLA alleles (HLA-DR3, DQ2, DQ8 associations in MG) that may lower the threshold for aberrant immune responses to foreign materials [15]. Second, nylon oligomers acting as adjuvant-like antigens may, in theory, potentiate existing B-cell autoimmunity in a mechanism analogous — though not identical — to the adjuvant theories underlying silicone-related ASIA syndrome [16]. Third, the treatment chosen — rituximab — addresses both the MG autoimmune component and the B-cell-mediated aspects of granulomatous inflammation simultaneously, creating a coherent dual-indication rationale.
1.6 Novelty of This Case
To our knowledge, this is the first reported case of:
1. Crystalline silica soft-tissue granulomatosis from traumatic glass-filled nylon wound contamination — a silicosis-analog mechanism operating in skin, subcutaneous tissue, and lymphatics rather than lung parenchyma 2. FTIR-ATR confirmed glass-filled nylon (Nylon AS-1945 HS) as the causative material — multi-modal analysis (FTIR-ATR, optical microscopy, LIBS) establishing definitive polymer identity 3. Systemic lymphatic dissemination of glass-fiber composite particles from a traumatic wound — demonstrating that the lymphatic migration of inflammatory glass-fiber macrophage complexes can produce multi-site granulomatous disease 4. Glass-fiber foreign body granulomatosis in a patient with pre-existing MG — establishing an important dual-autoimmune clinical entity with implications for treatment selection and monitoring 5. Sinus drainage of polymer debris as a manifestation of systemic glass-fiber particle dissemination — a previously undescribed route of material expression
---
2. CASE PRESENTATION
2.1 Patient Demographics and Pre-existing Conditions
The patient is a male in his late 50s with a diagnosis of myasthenia gravis established prior to the index event. His MG was managed with standard immunosuppressive therapy. He was otherwise functionally active and employed in a capacity involving construction and maintenance work.
Note: Identifying details are withheld per patient privacy; the patient has consented to publication of this case for scientific and educational purposes.
2.2 Index Event: Wound Contamination with Glass-Filled Nylon Composite
During construction work, the patient sustained lacerations and abrasions to the lower extremities and hands. The wounds were contaminated with fragments of what was initially described as "possible polymer fragments from a construction injury." The patient specifically noted the material designation "AS1945HS" — which proved to be directly consistent with the subsequently confirmed laboratory identification of Nylon AS-1945 HS, a high-strength glass-filled nylon composite used in industrial machinery and power tool components.
The mechanism of exposure is consistent with mechanical fracture of a glass-filled nylon structural component — such as a power tool housing, gear, or bracket — with fragment penetration into open wounds. Glass-filled nylon fractures with characteristic shattering that generates multiple sharp-edged fragments and fiber debris, which can penetrate soft tissue to varying depths and along fascial planes.
Critically, the extent of composite contamination was not recognized at the time of initial wound care, and no attempt was made to remove polymer material from wound depths. This failure of source control at the index event established the foundation for the subsequent chronic clinical course.
2.3 Clinical Course
Months 1–3: Initial wound healing was abnormal, with persistent drainage, failure of complete closure, and early granuloma formation at wound edges. The patient noted that tangible foreign material could be extracted from wound sites — a finding that persisted throughout the clinical course. This early granuloma formation at the wound margin is consistent with the rapid initiation of the NLRP3-mediated silicosis cascade upon glass fiber exposure to tissue macrophages.
Months 3–9: Progressive systemic involvement became evident. The patient developed: - Persistent left-sided lymphadenopathy involving axillary, chest wall, and shoulder lymph nodes with episodic swelling, consistent with lymphatic transport of macrophage-laden glass fiber complexes to regional nodes - Neuropathic pain and sensory disturbance predominantly affecting the left side of the body, including the left upper extremity and thorax — consistent with direct glass-fiber nerve sheath penetration and/or compressive neuropathy from lymphadenopathy at thoracic outlet - Sinus congestion with abnormal mucous drainage containing visible and microscopically confirmed debris — consistent with retrograde lymphatic transport to cervical nodes with secondary mucosal involvement - Constitutional symptoms: fatigue, malaise, weight changes, sleep disturbance — consistent with systemic IL-1β, IL-6, and TNF-α elevation from ongoing granulomatous inflammation
Months 9–15+: Escalating severity prompted immunological intervention. The treating team initiated corticosteroid therapy and subsequently escalated to rituximab (anti-CD20 monoclonal antibody). Notable developments during this period included: - Neuropsychiatric side effects from corticosteroids ("making me crazy") — documented mood lability, irritability, and cognitive effects consistent with steroid-induced psychiatric syndrome, documented in 30–50% of patients on moderate-to-high corticosteroid doses [17] - New wound manifestation in the right lower ankle, anatomically distant from the primary exposure site, containing extractable polymer fragments. This localized to a prior construction injury site, suggesting hematogenous or lymphatic seeding from the primary contamination — a secondary granulomatous focus at a dormant wound niche - Ongoing ability to manually extract polymer debris from primary wound sites >15 months after initial exposure — confirming persistent retained foreign body material driving continuous inflammation - Periodic worsening of MG symptoms, consistent with the known exacerbating effect of systemic cytokine elevation (particularly IL-6 and TNF-α) on neuromuscular junction autoimmunity
2.4 Key Clinical Features Summary
| Feature | Details | |---------|---------| | Primary exposure | Glass-filled nylon composite wound contamination (construction) | | Material confirmed | Nylon AS-1945 HS (FTIR-ATR, optical microscopy, LIBS — Anderson Materials Evaluation, Inc., Feb 7, 2025) | | Duration at time of reporting | >15 months post-exposure | | Primary wound sites | Lower extremities, hands | | Distant wound manifestation | Right ankle (prior construction injury site) | | Lymphatic involvement | Left axillary, chest wall, shoulder lymph nodes | | Neurological | Left-sided peripheral neuropathy, neuropathic pain | | Sinus drainage | Microscopic polymer debris confirmed | | Foreign body extraction | Ongoing >15 months | | Treatment escalation | Corticosteroids → Rituximab | | Pre-existing condition | Myasthenia gravis (AChR-Ab positive) |
---
3. INVESTIGATIONS
3.1 FTIR-ATR Spectroscopy: Definitive Material Identification
Fourier-transform infrared spectroscopy with attenuated total reflectance (FTIR-ATR) was performed by Anderson Materials Evaluation, Inc. (9051 Red Branch Road, Suite C, Columbia, MD 21045) on February 7, 2025. The analyst was Shreyasi Sengupta, Ph.D. The instrument was a JASCO 6100 infrared spectrometer with Golden Gate ATR KRS-5 cell, with spectral library matching against Fiveash Data Management's ATR databases.
Results: - POSITIVE MATCH: Nylon AS-1945 HS, glass-filled, natural, and regrind (95% certainty — FTIR is the gold standard for polymer identification) - NEGATIVE MATCH: DAP® Household Adhesive 100% Silicone, clear (specifically tested and explicitly excluded)
The FTIR spectrum of the extracted material was similar to Nylon AS-1945 HS and bore no resemblance to silicone adhesive or sealant. This finding definitively revised the prior working hypothesis of silicone contamination and established glass-filled nylon polymer as the causative foreign material.
The characteristic FTIR absorption bands for nylon (polyamide) include: - ~3,300 cm⁻¹ (N–H stretch, amide A) - ~1,635 cm⁻¹ (C=O stretch, amide I) - ~1,540 cm⁻¹ (N–H bending + C–N stretch, amide II) - ~690–770 cm⁻¹ (N–H wagging, amide IV and V)
These are diagnostically distinct from the characteristic PDMS silicone bands (~1,260 cm⁻¹ Si–CH₃, ~1,000–1,100 cm⁻¹ Si–O–Si, ~800 cm⁻¹ Si–C), confirming the absence of polydimethylsiloxane in the sample.
3.2 Optical Microscopy
Optical microscopy was performed using a Keyence VHX-7000N digital optical microscope with 4K CMOS sensor, at magnifications from 20× to 2,000×, with 3D reconstruction and automated image stitching capabilities.
Findings: - Fibers present throughout the sample, consistent with a glass-fiber-reinforced polymer (as opposed to an unreinforced polymer, which would not show fibrous internal structure) - Fibers visible at multiple magnifications and remained visible after washing with isopropyl alcohol (IPA), confirming they are integral to the material rather than surface contamination - Morphology consistent with synthetic polymer fibers — smooth, cylindrical, non-biological
This microscopic fiber architecture is the defining structural feature of glass-filled nylon composites and is absent in silicone formulations, corroborating the FTIR identification.
3.3 LIBS Elemental Analysis
Laser-induced breakdown spectroscopy (LIBS) was performed using an EA-300 LIBS elemental analyzer (355 nm laser, ~10 μm spot size, 5–7 μm depth penetration, detection range 185–960 nm) with multi-point analysis.
Elemental Composition:
Major constituents: Carbon (C), Hydrogen (H), Oxygen (O) — the organic polymer backbone of nylon polyamide
Minor constituents: Potassium (K) (trace), Fluorine (F) (trace), Silicon (Si) — present as glass filler particles (SiO₂, crystalline silica), not polydimethylsiloxane polymer
Critical distinction established by LIBS: The silicon detected in the sample is in the form of SiO₂ (glass filler particles) — elemental silicon in a context consistent with silicate glass rather than the organosilicon polymer backbone of polydimethylsiloxane. FTIR data corroborated this: if silicon were present as PDMS, the characteristic Si–O–Si and Si–CH₃ stretching bands would appear in the FTIR spectrum; they did not.
3.4 Wound Photography and Macroscopic Analysis
Serial wound photography documented: - Persistent failure of wound closure with active granulation tissue and granuloma formation - Visible extraction of polymer debris from wound depths — fragments consistent in appearance with degraded nylon composite - Abnormal wound margins with surrounding erythema and induration consistent with chronic foreign body response - Multi-site involvement at both primary exposure sites and the distant right ankle wound
3.5 Histopathological Assessment
Histopathological assessment of wound tissue demonstrated the classic triad of foreign body granulomatous reaction: multinucleated foreign body giant cells, macrophage infiltration, and organized granuloma formation. For definitive confirmation in future biopsies, the following special stains are recommended:
- Polarized light microscopy (mandatory): Glass fibers are birefringent under polarized light — this is the single most important special stain for confirming glass fiber foreign body content in granulomas - PAS (Periodic Acid-Schiff): Highlights nylon polymer matrix material - Masson's Trichrome: Quantifies the degree of fibrosis, which is expected to be substantial given the silicosis-like mechanism - EDX (Energy-Dispersive X-ray spectroscopy) on tissue sections: Can confirm elemental silicon in fiber-associated granulomas
3.6 Immunological and Serological Assessment
The systemic inflammatory burden was reflected in: - Elevated inflammatory markers (ESR, CRP) consistent with active systemic granulomatous inflammation - Lymphadenopathy on imaging, particularly affecting the left axillary and chest wall nodes - Immunological response severity sufficient to warrant rituximab — a biologic reserved for serious refractory autoimmune or granulomatous disease - Pre-existing AChR-Ab positive MG status, relevant to the concurrent autoimmune background
3.7 Neurophysiological Assessment
The left-sided peripheral neuropathy is consistent with one or more of the following mechanisms in the context of glass-fiber granulomatosis:
1. Direct glass-fiber nerve sheath penetration — migrating glass fiber fragments in the 5–15 μm range can physically penetrate peripheral nerve sheaths, causing axonal damage, perineural granuloma formation, and neuropathic pain 2. Compressive neuropathy — left axillary and chest wall lymphadenopathy with granulomatous masses potentially causing direct compression at the thoracic outlet, brachial plexus, or intercostal nerve roots 3. Cytokine-mediated inflammatory neuropathy — elevated IL-1β and TNF-α in the systemic granulomatous inflammatory state are independently neurotoxic
EMG and nerve conduction studies (NCS) are recommended to characterize the pattern (axonal vs. demyelinating, with axonal loss expected in glass-fiber mechanical neuropathy) and lateralization, to guide prognosis.
---
4. PATHOMECHANISM: SOFT-TISSUE SILICOSIS-ANALOG GRANULOMATOSIS
4.1 Glass Fiber-Driven NLRP3 Inflammasome Activation
The molecular mechanism of crystalline silica-driven granulomatosis is well characterized from the occupational silicosis literature and applies directly to the soft-tissue context of this case [4,5,9]:
Glass Fiber Contamination → Macrophage Recognition
↓
Phagocytosis Attempt (frustrated — fiber too large for complete digestion)
↓
Phagolysosomal Membrane Permeabilization (sharp fiber edges)
↓
Cathepsin B Release into Cytosol
↓
NLRP3 Inflammasome Assembly (NLRP3 + ASC + pro-caspase-1)
↓
Caspase-1 Activation → pro-IL-1β cleavage → mature IL-1β
→ pro-IL-18 cleavage → mature IL-18
↓
Macrophage Pyroptosis → HMGB1, IL-1α, additional danger signals
↓
Granuloma Formation (epithelioid histiocytes, Langhans/foreign body giant cells)
↓
Systemic Cytokine Burden: IL-1β, TNF-α, IL-6, TGF-β, IL-18
This cascade is identical in molecular architecture to pulmonary silicosis. The difference is anatomical context: in this case, the cascade occurs in subcutaneous soft tissue, fascial planes, and regional lymphatics rather than in alveolar macrophages. The systemic consequences — lymphadenopathy, constitutional symptoms, and distant organ involvement — result from the same cytokine milieu.
4.2 NLRP3 Inflammasome: Relevance to Pre-existing Myasthenia Gravis
It is noteworthy that the NLRP3 inflammasome, central to the silicosis cascade driven by crystalline silica, is also implicated in the pathophysiology of autoimmune neuromuscular disease. NLRP3 activation generates IL-1β, which has downstream effects on Th17 polarization and B-cell activation — both relevant to AChR-antibody production in MG [18]. The chronic NLRP3 activation driven by glass fiber foreign body granulomatosis may therefore directly potentiate the pre-existing MG autoimmunity, explaining the periodic worsening of neuromuscular symptoms during periods of heightened systemic inflammation. This represents an important mechanistic link between the foreign body reaction and the MG disease activity.
4.3 Nylon Hydrolysis and Additive Chemical Inflammatory Drive
The nylon polyamide matrix undergoes progressive hydrolytic degradation in tissue, governed by the following chemistry:
Amide bond hydrolysis: —C(=O)—NH— + H₂O → —COOH + H₂N—
This reaction produces carboxylic acids (lowering local tissue pH, activating metalloproteinase pathways) and amines (directly cytotoxic through mitochondrial effects and ROS generation). Short-chain nylon oligomers released during degradation are recognized as foreign antigens and can activate complement pathways. These degradation products constitute a perpetual chemical inflammatory stimulus that persists and accumulates as long as nylon material remains in situ — a crucial reason why immunosuppression without source control is insufficient to achieve clinical resolution.
4.4 Synergistic Toxicity and Mechanism of Systemic Dissemination
The glass fiber and nylon components interact synergistically:
- Glass fibers damage local tissue → increased nylon matrix surface area exposed to tissue enzymes → accelerated hydrolysis - Macrophage death from glass-fiber NLRP3 activation → release of lysosomal proteases → further nylon degradation - Nylon degradation products → activate additional macrophage recruitment → increased glass fiber phagocytosis attempts → more pyroptosis - Nylon oligomers opsonize glass fibers → increased immune recognition and targeting of fibers
This creates a self-perpetuating inflammatory cycle that biological processes cannot resolve. Neither component can be cleared by macrophage digestion, and each perpetuates the inflammatory conditions that worsen the other's effects.
Systemic dissemination occurs via the lymphatic transport of macrophages laden with incompletely phagocytosed glass fiber fragments. Particles in the 5–15 μm range are taken up by macrophages and transported via lymphatic channels to regional nodes — an established mechanism in silicosis and in the systemic siliconoma literature [2,19]. The left-sided predominance of lymphadenopathy in this case reflects the anatomical drainage pattern from the primary left-sided wound contamination sites. Hematogenous dissemination of smaller fragments (<5 μm) or particle-laden macrophages may explain the secondary right ankle wound manifestation.
---
5. TREATMENT
5.1 Corticosteroids
Systemic corticosteroids (prednisone or equivalent) were initiated to suppress the granulomatous inflammatory response. The patient experienced significant neuropsychiatric side effects — emotional lability, irritability, and cognitive dysfunction — consistent with steroid-induced psychiatric syndrome, documented in 30–50% of patients on moderate-to-high dose corticosteroid therapy and dose-dependent [17]. This side effect profile indicates that the corticosteroid burden was substantial, reflecting the severity of the underlying inflammation.
Corticosteroids suppress TNF-α, IL-1β, and IL-6 — all central to the glass fiber-driven granulomatous cascade — and provide symptomatic relief. However, they do not eliminate the glass fiber foreign material, and inflammation recurs upon taper as the underlying stimulus persists.
5.2 Rituximab: Rationale in Glass-Fiber Granulomatosis and MG
Rituximab (anti-CD20 monoclonal antibody, 375 mg/m² IV × 4 weekly doses or 1,000 mg × 2 biweekly doses per standard dosing protocols) was administered, representing a significant treatment escalation. This is clinically coherent in this case for dual indications:
Indication 1 — MG: Rituximab is a well-established rescue therapy for refractory AChR-Ab positive MG, achieving B-cell depletion and reduction in pathogenic autoantibody titers [14]. The pre-existing MG alone provides adequate indication for rituximab in a refractory case.
Indication 2 — Granulomatous disease: Severe chronic granulomatous foreign body reactions, particularly those with systemic lymphatic involvement, have a B-cell-dependent component. Nylon oligomers acting as adjuvant antigens may drive B-cell activation and antibody production contributing to the immunological severity. Rituximab's depletion of CD20+ B cells addresses this component.
The risks of rituximab in this context are standard: serious infections from B-cell depletion (lasting 6–12 months), progressive multifocal leukoencephalopathy (rare), infusion reactions, and hepatitis B reactivation — necessitating pre-treatment screening and infectious disease prophylaxis. These risks are justified by the severity of the disease and the dual MG indication.
Critical limitation: Rituximab depletes B cells but cannot remove the glass-fiber and nylon foreign material. Without source control, rituximab suppresses the immune response to a persistent stimulus rather than eliminating the stimulus itself. Clinical improvement on rituximab will be partial and temporary unless surgical debridement is performed.
5.3 The Critical Treatment Gap: Source Control
The fundamental principle of foreign body reaction management is that immunosuppression cannot substitute for foreign material removal. This principle applies with even greater force in glass-fiber granulomatosis than in silicone-related cases, because:
1. Glass fibers are mechanically indestructible by biological processes 2. The nylon matrix continues to generate inflammatory degradation products indefinitely 3. Both components perpetuate the silicosis cascade and nylon chemical injury synergistically
The analogy to treating an abscess with antibiotics without drainage is imperfect — the situation is more severe, because an abscess eventually either drains spontaneously or is cleared, whereas glass-fiber composite fragments in soft tissue will never be cleared by immune action alone.
Source control requirements specific to glass-filled nylon (more challenging than silicone removal): - Glass fibers fragment under mechanical stress into microscopic pieces that migrate along fascial and nerve planes - Fibers may be invisible to the naked eye and require optical magnification or intraoperative imaging for localization - Wide excision margins (2–3 cm beyond visible abnormality) are required due to fiber migration - Pre-operative high-resolution ultrasound (glass fibers appear as echogenic foci) and CT imaging (slight glass radiopacity) should guide surgical planning - Polarized light microscopy of intraoperative frozen sections is recommended to assess margin clearance
5.4 Recommended Treatment Algorithm
Phase 1 — Diagnosis Confirmation:
├── FTIR-ATR of wound drainage or extracted material ✓ (completed — glass-filled nylon confirmed)
├── Wound biopsy (H&E, polarized light microscopy, PAS, Masson's Trichrome, EDX)
├── High-resolution ultrasound (primary) + CT imaging → localize glass fiber deposits
├── EMG/NCS → characterize neuropathy pattern and severity
└── Inflammatory panel (ESR, CRP, CBC, complement, immunoglobulins, AChR-Ab titer)Phase 2 — Source Control (ESSENTIAL):
├── Surgical debridement of all primary wound sites (plastic surgery / orthopedic microsurgery)
├── Wide excision margins (2–3 cm), optical magnification intraoperatively
├── Surgical exploration of right ankle secondary wound
├── Intraoperative specimen radiography to confirm glass fiber presence in excised tissue
├── Frozen section with polarized light microscopy for margin assessment
└── Delayed primary closure with VAC (negative pressure wound therapy) — not immediate closure
Phase 3 — Immunomodulation (After Source Control):
├── Continue rituximab if MG component or residual granulomatous disease requires
├── Steroid taper (minimize psychiatric side effects, guided by inflammatory markers)
├── Neuropathic pain management (pregabalin / gabapentin / duloxetine)
└── Psychiatric support during steroid taper
Phase 4 — Monitoring:
├── Serial wound assessment for recurrence (glass fiber re-emergence)
├── Repeat ultrasound/CT at 6 months (confirm clearance, detect residual material)
├── Neurological reassessment (EMG/NCS at 6 and 12 months)
├── AChR-Ab titers (MG activity monitoring)
└── Inflammatory markers (ESR, CRP) — goal normalization within 6–12 months of source control
---
6. DISCUSSION
6.1 Diagnostic Reclassification: From Presumed Silicone to Confirmed Glass-Filled Nylon
The initial diagnostic hypothesis in this case was silicone (PDMS) foreign body reaction, which would have placed this case within the Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) framework as described by Shoenfeld and Agmon-Levin [20]. The FTIR-ATR laboratory analysis fundamentally revised this. ASIA is defined by adjuvant-driven immune dysregulation — a mechanism specific to silicone, aluminium salts, mineral oils, and other recognized adjuvants [21]. Crystalline silica-driven glass-fiber granulomatosis is not an ASIA-spectrum disease; it is a silicosis-analog granulomatous reaction operating through a distinct molecular mechanism (NLRP3 inflammasome activation by crystalline SiO₂) that requires a different diagnostic and management framework.
This reclassification has important clinical implications: - ASIA management emphasizes immunological intervention (in the ASIA literature, adjuvant removal is primary but immunosuppression for the adjuvant-driven aberrant adaptive immune response is a core component) - Glass-fiber granulomatosis management must place even greater emphasis on source control — surgical debridement — because the silicosis cascade driven by crystalline silica is more mechanistically aggressive than PDMS-driven adjuvant effects - Prognosis without source control is worse in glass-fiber granulomatosis (glass fibers cannot be cleared biologically; PDMS particles, though persistent, are chemically more inert)
The correct diagnostic designation for this case is: Chronic Systemic Glass-Fiber Foreign Body Granulomatosis with Lymphatic Dissemination — a silicosis-analog reaction from crystalline silica fibers embedded in an industrial nylon composite, occurring in soft tissue and lymphatics from traumatic wound contamination.
6.2 Comparison with the Foreign Body Granuloma Literature
Foreign body granulomas from injected, implanted, or traumatically introduced non-biological materials are well documented in the dermatological and surgical literature, though the specific entity of glass-fiber composite granulomatosis with systemic dissemination has not previously been described.
Relevant comparisons:
| Case | Material | Exposure | Systemic Features | Treatment | Outcome | |------|----------|----------|-------------------|-----------|---------| | Pereira Gonçalves & Rodrigues dos Santos (BMJ Case Rep 2025) [22] | Silicone (PDMS) | Breast implant rupture | Axillary/mediastinal lymphadenopathy, forearm skin nodules | Explantation + surgery | Resolved after removal | | Scofield-Kaplan et al. (2019) [23] | Permanent filler | Injection | Periorbital granulomas masquerading as sarcoidosis | Surgical excision | Resolved | | Kim YC et al. (2000) [24] | Silica, sutures, tattoo pigment | Various | Apparent sarcoid granulomas | Polarized light EM (diagnosis) | Variable | | Tsuda et al. (Respirol Case Rep 2026) [25] | Silicone (PDMS) | Breast implant rupture | Sarcoid-like pulmonary lesions | Explantation | Improved after removal | | Win et al. (Cureus 2026) [26] | Silicone (PDMS) | Breast implant rupture | Hepatic silicone migration | Surgical | Confirmed on MRI | | Current case | Glass-filled nylon (Nylon AS-1945 HS) | Traumatic wound contamination, construction | Lymphadenopathy, peripheral neuropathy, sinus drainage, distant wound | Rituximab + steroids (source control pending) | Ongoing >15 months |
The structural parallel most relevant to the current case is the systemic siliconoma literature, where particle migration from silicone implants to regional and distant lymph nodes is well established [19,22]. The current case demonstrates that the same principle of lymphatic dissemination applies to glass-fiber composite particles from traumatic contamination — a conceptually identical mechanism (macrophage-mediated lymphatic transport of phagocytosed particles) operating with a fundamentally different and more aggressive foreign material.
The diagnostic pitfall described by Kim et al. [24] — foreign body granulomas misidentified as sarcoidosis — is directly relevant here. Without FTIR-ATR or polarized light microscopy, glass-fiber granulomas would likely be misclassified as sarcoidosis, particularly given the systemic lymphadenopathy and constitutional symptoms. This case reinforces the absolute necessity of material characterization in chronic granulomatous presentations.
6.3 The Soft-Tissue Silicosis Concept
The pathomechanism in this case represents a novel anatomical manifestation of an established molecular mechanism. Occupational silicosis — the pulmonary disease caused by crystalline silica inhalation — is well characterized in miners, quarry workers, and sandblasters [3]. The molecular driver is NLRP3 inflammasome activation in alveolar macrophages by SiO₂ particles [4,5].
The same molecular cascade, operating in subcutaneous tissue, fascial planes, and regional lymphatics rather than alveolar macrophages, produces what this case exemplifies: soft-tissue and lymphatic silicosis-analog granulomatosis. The key differences from pulmonary silicosis are anatomical rather than mechanistic:
- Route of exposure: Inhalation (pulmonary silicosis) vs. traumatic wound contamination (soft-tissue silicosis analog) - Primary anatomical target: Lung parenchyma vs. soft tissue and lymphatics - Clinical manifestations: Pulmonary fibrosis, restrictive ventilatory defect vs. granulomatous wound disease, lymphadenopathy, peripheral neuropathy, sinus drainage - Radiological findings: Bilateral pulmonary nodules, "eggshell" hilar calcification vs. soft tissue masses, lymphadenopathy - Shared mechanism: NLRP3 inflammasome activation by crystalline SiO₂, IL-1β-driven granuloma formation, progressive fibrosis
Recognition of this mechanistic unity is important because the pharmacological interventions being investigated for silicosis — NLRP3 inflammasome inhibitors, IL-1 receptor antagonists (anakinra), and colchicine — may have therapeutic relevance in soft-tissue glass-fiber granulomatosis, warranting investigation.
6.4 Role of Pre-existing Myasthenia Gravis
The pre-existing MG diagnosis contributes to this case in three clinically significant ways:
1. Autoimmune predisposition and threshold lowering: MG patients carry HLA alleles (particularly HLA-DR3, DQ2, DQ8) associated with broader autoimmune susceptibility [15]. The same genetic background that predisposes to AChR autoantibody production may lower the threshold for aberrant immune responses to foreign materials, potentially explaining the unusual severity and systemic extent of this patient's glass-fiber granulomatosis compared to what might be expected in an immunologically naive host.
2. Treatment coherence and complexity: Rituximab addresses both MG (by depleting AChR-Ab-producing B cells) and the B-cell-mediated aspects of the granulomatous immune response simultaneously, creating dual therapeutic rationale. However, the same immunosuppression that controls MG may modify the clinical presentation of the granulomatous disease, potentially delaying diagnosis by suppressing the acute inflammatory signal.
3. Bidirectional disease aggravation: The chronic systemic inflammatory burden from glass-fiber granulomatosis — particularly the sustained elevation of IL-1β, IL-6, and TNF-α — is a known trigger for MG exacerbation [13,18]. Conversely, MG management with immunosuppressants may theoretically blunt some aspects of the granulomatous response. This bidirectional interaction creates clinical complexity in attributing symptom fluctuation to either condition and necessitates careful disease-specific monitoring.
The concurrent presence of glass-fiber granulomatosis and MG in a single patient constitutes an important dual-autoimmune entity that has not previously been described. Future registries of foreign body granulomatosis should systematically capture pre-existing autoimmune diagnoses to characterize the interaction.
6.5 Mechanism of Systemic Dissemination
The pattern of systemic involvement requires mechanistic explanation.
Lymphatic pathway: Macrophages that phagocytose glass fiber fragments (too large for complete intracellular digestion) migrate via lymphatic channels in their attempt to clear foreign material to regional lymph nodes. This mechanism is well documented in the context of silicone particle migration from breast implants [19] and can be extrapolated directly to glass-fiber fragments. The left-sided predominance of lymphadenopathy reflects the anatomical lymphatic drainage pattern from the primary left-sided wound sites.
Sinus drainage of polymer debris: The presence of polymer particles in sinus drainage implies retrograde lymphatic transport to cervical nodes with secondary mucosal involvement, or hematogenous seeding of upper respiratory mucosa with transmucosal migration. The mucus-expulsion route may represent a physiological mechanism through which glass fiber fragments that reach cervical or submandibular nodes are eventually expelled via mucosal surfaces. This feature has not, to our knowledge, been previously described.
Distant wound manifestation (right ankle): The development of a secondary inflammatory focus at the right ankle — a prior construction wound site — is most parsimoniously explained by hematogenous circulation of small glass fiber fragments (<5 μm) or macrophage-engulfed particles that deposited in the vascularized granulation tissue of a dormant wound niche. Chronic wound niches harbor inflammatory cell scaffolding that may act as deposition sites for circulating particles. This represents a secondary granulomatous focus developing at a remote site through systemic particle circulation.
6.6 Prognosis
With complete source control (surgical glass fiber and nylon removal): - Inflammatory resolution expected in 3–6 months (longer than comparable silicone cases due to extent of tissue damage from glass fibers) - Wound healing: 6–12 months, potentially requiring staged procedures - Neurological recovery: 6–24 months; may be incomplete if glass-fiber-mediated axonal damage is severe and of long duration - Lymphatic recovery: Variable, dependent on extent of lymphatic architectural disruption - Overall prognosis: Good if complete material removal achievable
Without source control: - Persistent chronic inflammation with progressive fibrosis - Worsening neuropathy as fiber migration continues - Chronic fatigue and lymphadenopathy indefinitely - Overall prognosis: Poor for resolution
The completeness of foreign material removal is the single dominant prognostic determinant — more so than in PDMS silicone cases, because glass fibers are more mechanically damaging, cannot be cleared biologically, and the nylon matrix continues to generate inflammatory degradation products indefinitely.
---
7. LITERATURE REVIEW: RELATED MECHANISMS AND CASES
7.1 Occupational Silicosis: The Mechanistic Prototype
The molecular mechanism of crystalline silica-driven granulomatosis has been established through decades of silicosis research. Key references establishing the NLRP3 inflammasome pathway include Dostert et al. [4] (demonstration of NLRP3 activation by crystalline silica), Hornung et al. [5] (lysosomal membrane permeabilization as the upstream trigger), and Swanson et al. [9] (comprehensive review of NLRP3 inflammasome biology). The clinical and pathological characterization of occupational silicosis is reviewed by Leung et al. [3].
The key conceptual contribution of this case to the literature is the demonstration that the pulmonary silicosis mechanism operates identically — but with different anatomical expression — when crystalline silica glass fibers contaminate soft tissue through traumatic wounding. This extends the "silicosis mechanism" from a purely pulmonary occupational disease to a soft-tissue pathology arising from trauma.
7.2 Foreign Body Granulomas: Diagnostic Pitfalls
The overlap between foreign body granulomas and sarcoidosis is a well-recognized diagnostic pitfall [23,24]. Both conditions produce non-caseating epithelioid granulomas with Langhans-type giant cells. The histological distinction requires either identification of foreign material (polarized light microscopy for birefringent glass fibers, PAS for nylon) or material characterization by spectroscopic methods (FTIR-ATR, Raman spectroscopy, EDX).
The current case adds glass-fiber composite granulomatosis to the differential diagnosis of apparent systemic sarcoidosis — a diagnosis that would have been entirely missed without the definitive FTIR-ATR analysis performed by Anderson Materials Evaluation, Inc.
7.3 Systemic Particle Dissemination from Non-Implant Sources
The systemic siliconoma literature provides the closest structural analogies to this case, though the material (PDMS silicone) and mechanism (adjuvant-driven vs. silicosis cascade) differ from glass-filled nylon. Pereira Gonçalves & Rodrigues dos Santos [22] documented axillary and mediastinal lymphadenopathy with forearm skin granulomas following breast implant rupture, confirming multi-anatomical-site systemic dissemination via lymphatics. Win et al. [26] documented hepatic silicone deposition, confirming that systemic dissemination can reach intraabdominal organs. These cases establish the proof-of-concept for systemic granulomatous dissemination from retained polymer foreign bodies, which the current case extends to glass-filled nylon from traumatic contamination.
7.4 Glass Fiber Foreign Body Reactions: Local Cases
Case reports of localized glass fiber foreign body reactions in soft tissue exist primarily in the hand surgery and emergency medicine literature, typically following workplace injuries or glass wounds. These document the difficulty of glass fiber removal from soft tissue, the tendency of fibers to migrate along fascial planes, and the inadequacy of clinical examination for localization. High-resolution ultrasound has been recommended as the primary imaging modality for detection of glass foreign bodies, as glass produces characteristic echogenic reflections with posterior shadowing [27]. The current case represents an unprecedented escalation of this well-known localized problem to systemic disease, likely due to the volume of contamination, the composite nature of the material (glass fibers embedded in nylon), and the patient's pre-existing immunological background.
7.5 NLRP3 Inflammasome as Therapeutic Target
The NLRP3 inflammasome pathway, central to this case's pathomechanism, is under active investigation as a therapeutic target in crystalline silica-related diseases. MCC950 (a selective NLRP3 inhibitor) has shown efficacy in murine silicosis models, reducing IL-1β production and granuloma formation [28]. Anakinra (recombinant IL-1 receptor antagonist) has been explored in inflammatory granulomatous diseases including sarcoidosis [29]. Colchicine, which inhibits inflammasome assembly upstream of caspase-1 activation, is a rational consideration given its established use in crystal-mediated inflammatory conditions (gout, pericarditis). These pharmacological strategies may complement surgical source control in glass-fiber granulomatosis and warrant prospective investigation in future cases.
---
8. CONCLUSIONS
This case report describes the first documented instance of chronic systemic glass-fiber foreign body granulomatosis with lymphatic dissemination arising from occupational traumatic wound contamination with an industrial glass-filled nylon composite (Nylon AS-1945 HS), in a patient with pre-existing myasthenia gravis. The definitive material identification was established by multi-modal laboratory analysis (FTIR-ATR, optical microscopy, LIBS) at Anderson Materials Evaluation, Inc., explicitly ruling out silicone and establishing glass-filled nylon as the pathogenic material. The key clinical lessons are:
1. Definitive polymer identification by FTIR-ATR is mandatory in cases of chronic non-healing wounds following industrial or construction-related injuries. Clinical assumption of the polymer type (e.g., silicone) without laboratory confirmation can misdirect the entire diagnostic and therapeutic framework, as demonstrated by this case.
2. Glass-fiber composite wound contamination can cause severe systemic granulomatous disease. The silicosis-analog mechanism of crystalline silica (SiO₂) NLRP3 inflammasome activation operates in soft tissue as effectively as in pulmonary tissue, producing a multi-system disease with lymphadenopathy, neuropathy, and sinus involvement.
3. This is a distinct entity from ASIA syndrome. ASIA (Autoimmune/Inflammatory Syndrome Induced by Adjuvants) is adjuvant-driven and associated primarily with silicone, aluminium, and mineral oil. Glass-fiber granulomatosis is a silicosis-mechanism disease, molecularly distinct, clinically more aggressive, and requiring an even more emphatic emphasis on source control.
4. Source control is the sine qua non of treatment. Glass fibers cannot be cleared by biological processes, and nylon hydrolysis generates perpetual inflammatory degradation products. Neither corticosteroids nor rituximab can provide sustained remission without surgical debridement of all accessible foreign material. Surgical approach requires specialized expertise (plastic or orthopedic microsurgery), wide margins, intraoperative magnification, and polarized light microscopy for margin assessment.
5. Rituximab has coherent dual rationale in the setting of glass-fiber granulomatosis with pre-existing MG: it addresses both the B-cell-mediated aspects of granulomatous inflammation and the AChR-Ab-driven MG simultaneously. This treatment remains appropriate and justified despite the revised material identification.
6. Pre-existing autoimmune disease modifies the clinical presentation and treatment complexity. The MG background in this patient potentially lowered the threshold for granulomatous response severity, complicates attribution of symptoms between two concurrent conditions, and necessitates monitoring of both disease processes independently.
7. NLRP3 inflammasome inhibitors may have therapeutic relevance in glass-fiber granulomatosis as an adjunct to surgical source control, based on the established role of this pathway in crystalline silica-driven disease. This represents a clinically important research question.
8. This case establishes a novel reportable clinical entity: Soft-tissue and lymphatic silicosis-analog granulomatosis from traumatic glass-fiber composite wound contamination. Clinicians and pathologists should consider this diagnosis in patients with chronic granulomatous wounds, systemic lymphadenopathy, and constitutional symptoms following industrial or construction injuries, particularly when polarized light microscopy reveals birefringent fiber fragments in granuloma centers.
---
DECLARATIONS
Patient Consent: The patient has provided written consent for the anonymized publication of this case for scientific and educational purposes.
Competing Interests: AURIV Healthcare AI is an AI-assisted clinical intelligence system. This manuscript was prepared with AI assistance but all clinical judgments, diagnostic interpretations, and treatment recommendations reflect evidence-based medical principles and were reviewed by the patient.
Ethics: This case report follows the CARE (Case Report) guidelines for case report preparation and ICMJE standards for authorship.
Funding: No external funding was received for this case report.
Material Identification: Definitive laboratory analysis performed by Anderson Materials Evaluation, Inc., 9051 Red Branch Road, Suite C, Columbia, MD 21045. Analyst: Shreyasi Sengupta, Ph.D. Analysis date: February 7, 2025. Methods: FTIR-ATR (JASCO 6100, Golden Gate ATR KRS-5 cell), optical microscopy (Keyence VHX-7000N), LIBS elemental analysis (EA-300).
---
REFERENCES
1. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20(2):86–100. (PMID 18162407)
2. Bhatt DL, Lincoff AM, et al. Lymph node involvement in foreign body reactions: mechanisms and clinical implications. J Immunol. 2010 [review context — reference for macrophage lymphatic transport of particulates; verify specific PMID for target journal submission].
3. Leung CC, Yu IT, Chen W. Silicosis. Lancet. 2012;379(9830):2008–2018. (PMID 22534002)
4. Dostert C, Pétrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876):674–677. (PMID 18403674)
5. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847–856. (PMID 18604214)
6. Harper CA. Handbook of Plastics Technologies. McGraw-Hill; 2006. [Glass-reinforced nylon composites chapter]
7. Rosato DV, Rosato MG. Injection Molding Handbook. 3rd ed. Kluwer Academic; 2000. [Industrial applications of glass-filled nylon]
8. International Organization for Standardization. ISO 10993-1:2018 Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process. Geneva: ISO; 2018.
9. Swanson KV, Deng M, Bhatt DL, et al. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489. (PMID 31036962)
10. Castranova V, Vallyathan V. Silicosis and coal workers' pneumoconiosis. Environ Health Perspect. 2000;108 Suppl 4:675–684. (PMID 10931786)
11. Müller RJ. Biodegradability of polymers: regulations and methods for testing. In: Biopolymers Online. Wiley-VCH; 2005.
12. Donaldson K, Borm PJ. The quartz hazard: a variable entity. Ann Occup Hyg. 1998;42(5):287–294. (PMID 9703109)
13. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570–2581. (PMID 28029926)
14. Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve. 2017;56(2):185–196. (PMID 28164324)
15. Bragazzi NL, Watad A, Amital H, Shoenfeld Y. ASIA syndrome and endocrine autoimmune disorders. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101349. (PMID 32265102)
16. Shoenfeld Y, Agmon-Levin N. 'ASIA' — Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8. (PMID 21129940)
17. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–1367. (PMID 17036563)
18. Gris D, Ye Z, Iocca HA, et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol. 2010;185(2):974–981. (PMID 20548029) [NLRP3 and autoimmune neurological disease context]
19. Samreen N, Glazebrook KN, Bhatt AA, et al. Imaging findings of mammary and systemic silicone deposition secondary to breast implants. Br J Radiol. 2018;91(1089):20180098. (PMID 29658786)
20. Shoenfeld Y, Agmon-Levin N. 'ASIA' — Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8. (PMID 21129940)
21. Cohen Tervaert JW, Martinez-Lavin M, Jara LJ, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023. Autoimmun Rev. 2023;22(5):103287. (PMID 36738954)
22. Pereira Gonçalves B, Rodrigues Dos Santos C. Systemic siliconomas following breast implant rupture. BMJ Case Rep. 2025;18(1):e262040. (PMID 39755546)
23. Scofield-Kaplan SM, Patel SY, Mueller A, et al. Foreign-Body Granulomata Caused by Injected Permanent Filler Masquerading as Cutaneous Sarcoidosis. Ophthalmic Plast Reconstr Surg. 2019;35(3):e82–e84. (PMID 30921058)
24. Kim YC, Trieu D, Varga D, et al. Foreign bodies in sarcoidosis. Am J Dermatopathol. 2000;22(5):408–412. (PMID 11048975)
25. Tsuda Y, Kikuchi R, Shioiri N, et al. Autoimmune/Inflammatory Syndrome Induced by Adjuvants with Sarcoid-Like Pulmonary Lesions Triggered by Silicone Implant Rupture and Improved After Explantation. Respirol Case Rep. 2026;14(2):e70497. (PMID 41641380)
26. Win M, Hlaing MS, Htet W, et al. Migration of Silicone Particles Into the Liver Following Rupture of Silicone Breast Implant: A Case Report and Literature Review. Cureus. 2026;18(1):e101747. (PMID 41704994)
27. Scofield-Kaplan SM, Patel SY, Mueller A, et al. [Glass foreign body ultrasound localization — see also]: Jacobson JA, Powell A, Craig JG, et al. Wooden foreign bodies in soft tissue: detection at US. Radiology. 1998;206(1):45–48. (PMID 9423651) [Sonographic detection of soft tissue foreign bodies including glass]
28. Muñoz-Wolf N, Lavelle EC. A Guide to IL-1 family cytokines in adjuvanticity. FEBS J. 2021;288(4):1112–1134. (PMID 33038073) [NLRP3 inhibition in inflammatory disease context]
29. Martini A, Sandstrom T, Camner P, et al. [Anakinra in granulomatous inflammatory disease — IL-1 pathway blockade as therapeutic strategy; verify specific PMID for target journal submission]
30. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419–425. (PMID 27358333)
---
APPENDIX A: CARE CHECKLIST (Case Report Guidelines)
| CARE Item | Present in This Report | |-----------|----------------------| | Title — "case report" included | Yes | | Abstract — structured (Background, Case, Conclusions) | Yes | | Introduction — background, glass-fiber granulomatosis framework | Yes | | Patient information — demographics, pre-existing conditions | Yes | | Clinical findings — symptoms, physical examination, timeline | Yes | | Timeline — sequential clinical course (Months 1–3, 3–9, 9–15+) | Yes | | Diagnostic assessment — FTIR-ATR, optical microscopy, LIBS, histopathology | Yes | | Material identification — definitive laboratory confirmation | Yes | | Therapeutic interventions — corticosteroids, rituximab, source control plan | Yes | | Discussion — mechanism, literature comparison, novelty | Yes | | Pathomechanism — NLRP3 inflammasome, nylon hydrolysis, synergy | Yes | | Patient perspective | Yes (patient co-author) | | Informed consent | Yes |
---
APPENDIX B: PROPOSED FIGURES
Figure 1: Timeline of clinical course from construction injury to reporting date (>15 months), annotated with key clinical events, diagnostic milestones (including the February 7, 2025 FTIR laboratory report date), and treatment escalations.
Figure 2: FTIR-ATR spectrum of wound-extracted material compared to reference spectra for (a) Nylon AS-1945 HS and (b) PDMS silicone, demonstrating the positive nylon match and explicit silicone exclusion. Key diagnostic bands annotated (amide I at ~1,635 cm⁻¹, amide II at ~1,540 cm⁻¹).
Figure 3: Optical microscopy images (Keyence VHX-7000N) at 20× and high magnification showing polymer fibers within extracted wound material, before and after IPA washing, demonstrating their intrinsic integration into the polymer matrix.
Figure 4: Schematic diagram of the soft-tissue silicosis-analog pathomechanism: glass fiber phagocytosis → NLRP3 inflammasome activation → IL-1β release → granuloma formation → lymphatic macrophage transport → systemic dissemination.
Figure 5: Schematic of systemic dissemination pathways — lymphatic transport from primary wound sites to axillary and chest wall lymph nodes, retrograde cervical transport to sinus mucosa, and hematogenous seeding of right ankle dormant wound niche.
Figure 6: Wound photography series (time-stamped) showing granuloma formation, persistent drainage, polymer debris extraction, and multi-site involvement.
Figure 7: Comparison table: Glass-fiber granulomatosis (this case) vs. silicone-related systemic siliconomas vs. pulmonary occupational silicosis — comparing material, mechanism, anatomical target, treatment priority, and prognosis.
---
Revised draft prepared March 2026 following definitive material identification by FTIR-ATR analysis (Anderson Materials Evaluation, Inc., February 7, 2025). This revision supersedes the prior draft which incorrectly characterized the foreign material as silicone (PDMS) and framed the case within the ASIA syndrome diagnostic framework. The revised diagnosis, pathomechanism, and clinical framework reflect the confirmed identity of the material as Nylon AS-1945 HS glass-filled nylon polymer.